Aptorum Group Ltd
NASDAQ:APM

Watchlist Manager
Aptorum Group Ltd Logo
Aptorum Group Ltd
NASDAQ:APM
Watchlist
Price: 0.97 USD -3% Market Closed
Market Cap: 6.9m USD

Aptorum Group Ltd
Investor Relations

Aptorum Group Ltd. is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs. The company is pursuing therapeutic projects in neurology, infectious diseases, gastroenterology, oncology and other. Its projects include Smart-Act series, Acticule series, RPIDD, Nativus series and Claves series. SMART-ACT is a drug delivery platform, focused on orphan diseases. SMART-ACT pipeline includes SACT-1 and SACT-COV19. Its Acticule series includes ALS-4, ALS-1 and ALS-2/3. ALS-4 is an anti-virulent, non-bacterial drug candidate for staphylococcus aureus infections. ALS-1 is an antiviral therapeutic against Influenza A. ALS-3/3 is an anti-virulent, non-bacterial approach therapeutics targeting Gram-positive bacteria. RPIDD is therapeutic against infection disease. Nativus series includes NativusWell (NLS-2), nutraceutical supplement targeting women who are between 45 ad 65 years old and experiencing menopausal, premenopausal, postmenopausal syndrome.

Show more
Loading

Earnings Calls

No Earnings Calls Available

Management

Mr. Chung Yuen Huen
Founder, CEO & Non-Executive Director
No Bio Available
Mr. Kwok Kuen Wong
Head of Finance
No Bio Available

Contacts

Address
London
17 Hanover Square
Contacts
+442080929299.0
www.aptorumgroup.com